Reduced MLH1 Expression in Breast Tumors After Primary Chemotherapy Predicts Disease-Free Survival
- 1 January 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (1) , 87
- https://doi.org/10.1200/jco.2000.18.1.87
Abstract
PURPOSE: Loss of function or expression of the mismatch repair protein MLH1 and the tumor suppressor protein p53 have been implicated in acquired resistance to anticancer drugs. We have compared th...Keywords
This publication has 32 references indexed in Scilit:
- Primary chemotherapy in breast cancerBiomedicine & Pharmacotherapy, 1998
- No significant predictive value of c- erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancerInternational Journal of Cancer, 1998
- Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancerBritish Journal of Cancer, 1998
- Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.Journal of Clinical Oncology, 1998
- Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer.Journal of Clinical Oncology, 1998
- hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agentsOncogene, 1997
- Multidrug Resistance in Breast Cancer: a Meta-analysis of MDR1/gp170 Expression and Its Possible Functional SignificanceJNCI Journal of the National Cancer Institute, 1997
- Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST piBritish Journal of Cancer, 1996
- Preoperative chemotherapy in operable breast cancerThe Lancet, 1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992